Article
Oncology
Meletios A. Dimopoulos, Xavier Leleu, Philippe Moreau, Paul G. Richardson, Anna Marina Liberati, Simon J. Harrison, H. Miles Prince, Enrique M. Ocio, Sylvie Assadourian, Frank Campana, Laure Malinge, Dorothee Semiond, Helgi van de Velde, Kwee Yong
Summary: The ICARIA-MM study found that in patients with renal impairment and relapsed/refractory multiple myeloma, the Isa-Pd treatment regimen improved progression-free survival, overall response rate, and complete renal response rates compared to Pd.
Review
Oncology
Paul G. Richardson, Simon J. Harrison, Sara Bringhen, Fredrik Schjesvold, Kwee Yong, Frank Campana, Solenn Le-Guennec, Sandrine Mace, Meletios A. Dimopoulos
Summary: The addition of isatuximab to pomalidomide and dexamethasone improves progression-free survival and disease response rates across different subgroups, regardless of prognostic factors.
Article
Oncology
Meral Beksac, Ivan Spicka, Roman Hajek, Sara Bringhen, Tomas Jelinek, Thomas Martin, Gabor Mikala, Philippe Moreau, Argiris Symeonidis, Andreea M. Rawlings, Helgi van de Velde, Paul G. Richardson
Summary: The studies showed that isatuximab combined with pomalidomide and dexamethasone or carfilzomib and dexamethasone improved progression-free survival in patients with relapsed and/or refractory multiple myeloma, especially in those with soft-tissue plasmacytomas. The treatment had a similar median PFS compared to patients without soft-tissue plasmacytomas who received standard therapy. Safety profiles were reported individually per study.
Article
Oncology
Sara Bringhen, Ludek Pour, Vladimir Vorobyev, Filiz Vural, Krzysztof Warzocha, Lotfi Benboubker, Youngil Koh, Vladimir Maisnar, Lionel Karlin, Michel Pavic, Frank Campana, Solenn Le Guennec, Fatima Menas, Helgi van de Velde, Paul G. Richardson
Summary: In patients with relapsed/refractory multiple myeloma, the combination therapy of isatuximab plus pomalidomide-dexamethasone extended median progression-free survival (PFS) and improved overall response rate (ORR), regardless of prior lines of therapy or refractory status.
Article
Oncology
Kazutaka Sunami, Takashi Ikeda, Shang-Yi Huang, Ming-Chung Wang, Youngil Koh, Chang Ki Min, Su-Peng Yeh, Morio Matsumoto, Michihiro Uchiyama, Satoshi Iyama, Chihiro Shimazaki, Jae Hoon Lee, Kihyun Kim, Hitomi Kaneko, Jin Seok Kim, Tung-Liang Lin, Frank Campana, Keisuke Tada, Shinsuke Iida, Kenshi Suzuki
Summary: Data from the phase III ICARIA-MM study demonstrated that isatuximab plus pomalidomide and dexamethasone improved progression-free survival and response rates in patients with relapsed/refractory multiple myeloma. The analysis also confirmed the efficacy and safety of this treatment combination in Japanese, Korean, and Taiwanese patients, supporting its use in East Asia.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Oncology
Paul G. Richardson, Aurore Perrot, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Laure Malinge, Franck Dubin, Helgi van de Velde, Kenneth C. Anderson
Summary: The addition of isatuximab to pomalidomide-dexamethasone resulted in a significant improvement in overall survival for patients with relapsed and refractory multiple myeloma, establishing a new standard of care for this population. Ongoing follow-up for final overall survival analysis is warranted.
Article
Hematology
Simon J. Harrison, Aurore Perrot, Adrian Alegre, David Simpson, Ming Chung Wang, Andrew Spencer, Sosana Delimpasi, Cyrille Hulin, Kazutaka Sunami, Thierry Facon, Philip Vlummens, Kwee Yong, Frank Campana, Marlene Inchauspe, Sandrine Mace, Marie-Laure Risse, Helgi Velde, Paul Richardson
Summary: The ICARIA-MM trial demonstrated that isatuximab plus pomalidomide-dexamethasone provides consistent benefits in terms of improving progression-free survival and overall response rate in both high-risk and patients with gain(1q21) abnormality. Despite higher rates of grade >= 3 adverse events, isatuximab did not increase treatment discontinuation or mortality events in high-risk patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Pharmacology & Pharmacy
Tommy R. Li, Manash Chatterjee, Mallika Lala, Anson K. Abraham, Tomoko Freshwater, Lokesh Jain, Vikram Sinha, Dinesh P. de Alwis, Kapil Mayawala
Summary: This article outlines a pragmatic dose selection strategy for immuno-oncology and other targeted monoclonal antibodies, using pembrolizumab as an example. Through simulations and randomized dose comparison studies, the recommended phase II dose (RP2D) of 200 mg every 3 weeks was confirmed as the pivotal dose for achieving optimal target engagement.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Oncology
Thomas G. Martin, Nina Shah, Joshua Richter, David H. Vesole, Sandy W. Wong, Chiung-Yu Huang, Deepu Madduri, Sundar Jagannath, David S. Siegel, Noa Biran, Jeffrey L. Wolf, Samir Parekh, Hearn J. Cho, Pamela Munster, Shambavi Richard, Samira Ziti-Ljajic, Ajai Chari
Summary: This study evaluated the safety and efficacy of Isa and K combination therapy in patients with RRMM. Despite heavily pretreated patients, 70% responded to the treatment, with a median progression-free survival of 10.1 months.
Article
Oncology
Rahul Banerjee, Mimi Lo, Thomas G. Martin
Summary: Isa-Kd is a new treatment option for relapsed multiple myeloma, based on the Phase III IKEMA trial. This combination therapy has shown efficacy and tolerability in patients with myeloma, receiving regulatory approval in the USA and Europe. Isa-Kd has the potential to become a treatment option for relapsed multiple myeloma.
Review
Oncology
Fei Shen, Weidong Shen
Summary: In this review, the structure, mechanisms of action, pharmacokinetics, pharmacogenetics, and safety profile of isatuximab in multiple myeloma are summarized. Additionally, isatuximab is compared with daratumumab in terms of mechanism and efficacy.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2022)
Review
Oncology
Jose-angel Hernandez-Rivas, Rafael Rios-Tamayo, Cristina Encinas, Rafael Alonso, Juan-Jose Lahuerta
Summary: The increase in therapeutic alternatives for multiple myeloma patients has made the clinical scenario more complex. The choice of previously unused drugs and previous therapeutic regimens have a greater impact on treatment efficacy than the characteristics of the disease itself. New generation drugs have been developed to fight relapsed/refractory multiple myeloma.
BIOMARKER RESEARCH
(2022)
Article
Oncology
Thierry Facon, Philippe Moreau, Thomas G. Martin, Ivan Spicka, Albert Oriol, Youngil Koh, Andrew Lim, Gabor Mikala, Laura Rosinol, Munci Yagci, Michele Cavo, Kwee Yong, Marie-Laure Risse, Gaelle Asset, Sandrine Schwab, Gracia Martinez
Summary: This subgroup analysis evaluated the efficacy and safety of the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib-dexamethasone (Isa-Kd) versus Kd in older and younger patients with relapsed multiple myeloma. The results showed that Isa-Kd provided consistent benefits and manageable safety profile in elderly patients.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
S. R. Goldsmith, L. Liu, F. Covut
Summary: Isatuximab, an IgG1 monoclonal antibody targeting CD38, has regulatory approval in combination regimens for patients with relapsed/refractory multiple myeloma. It offers unique aspects such as a mechanism of action involving more direct myeloma-cell inhibition and killing, and ongoing studies are exploring its potential in combination with other therapies across different diseases.
Article
Medicine, General & Internal
Precious O. Idogun, Zeina Kayali
Summary: This article reports a case of severe ocular infusion reaction in a patient receiving isatuximab treatment. The patient showed symptomatic improvement after receiving appropriate treatment and was discharged.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
